Cassava Sciences | PTIE - Operating Expenses


Cassava Sciences reported $11.17M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Abbott USD 11.66B 1.2B Sep/2026
Amgen USD 11.69B 6.9B Jun/2026
Biogen USD 2.32B 663.6M Sep/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Cassava Sciences USD 11.17M 2.38M Mar/2026
Eisai JPY 209.6B 6.14B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Geron USD 52.07M 6.73M Mar/2026
J&J USD 18.93B 1.09B Sep/2026
Merck USD 15.77B 2.4B Jun/2026
Novartis USD 10.2B 912M Jun/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026